Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Agent for the treatment of alopecia

Inactive Publication Date: 2012-09-20
ENDO YORI +1
View PDF3 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0157]As is clear from the case tests described below, the treatment agent of the present invention containing a natriuretic peptide (NP) as an active ingredient can outstandingly improve alopecia areata, androgenetic alopecia, female pattern alopecia, seborrheic alopecia, alopecia pityroides, postpartum alopecia, senile alopecia, and cancer chemotherapy drug-induced alopecia. Furthermore, the treatment agent of the present invention can restore white hair to black hair or its original color. Moreover, in accordance with use of the treatment agent of the present invention, dandruff is decreased. Furthermore, the treatment agent of the present invention does not have side effects such as an itching sensation, irritation, and feminization, and there is no recurrence of alopecia areata and cancer chemotherapy drug-induced alopecia for at least half a year even if its use is stopped.
[0158]The treatment agent of the present invention can be anticipated to be useful as a very effective treatment drug for androgenetic alopecia, for which sufficient therapeutic effects cannot be obtained by the conventional minoxidil or finasteride, and alopecia areata, for which there are hardly any effective treatment methods. Furthermore, the treatment agent of the present invention has marked hair growth, hair restoration, and hair thickening effects for female pattern alopecia, seborrheic alopecia, alopecia pityroides, postpartum alopecia, senile alopecia, cancer chemotherapy drug-induced alopecia, and alopecia due to radiation exposure, for which there are hardly any therapies, can dramatically decrease the amount of hair falling out, and can prevent the progress of hair loss.
[0159]Moreover, the treatment agent of the present invention can convert miniaturized hair root into large hair root that grows terminal hair and can change the hair quality so that it is harder and thicker. Furthermore, the treatment agent of the present invention promotes hair growth of terminal hair, prolongs the growth phase, and increases long hair. Moreover, the treatment agent of the present invention promotes hair restoration and hair lengthening and speeds up the hair lengthening rate.
[0160]Furthermore, the treatment agent of the present invention can increase the number of hairs per hair follicle. The treatment agent of the present invention promotes hair growth and hair restoration in the frontal region or M-shaped site, which is intractable, and has a hair growth effect, hair restoration effect, and hair thickening effect for alopecia that is classified as Va, VI, or VII on the Hamilton-Norwood scale, which is wide area, severe androgenetic alopecia. The treatment agent of the present invention restores hair for alopecia areata and has the effect of preventing restored hair from falling out such that newly grown hair does not fall out after its application is stopped.
[0161]The treatment agent of the present invention can in particular dramatically improve severe alopecia on the adult head that has been difficult to treat and causes problems in social life, without any side effects at all. The treatment agent of the present invention is not only effective for intractable alopecia but also exhibits the same effects for both males and females and for both adults and younger people.
[0162]In the case of minoxidil and finasteride, which are conventionally used, there is the serious problem that when their use is stopped, the severity prior to use immediately returns, but in the present invention, this defect is not seen for alopecia areata, postpartum alopecia, cancer chemotherapy drug-induced alopecia, and alopecia due to radiation exposure. Furthermore, with regard to androgenetic alopecia, not only for the crown, for which a hair thickening effect by finasteride was confirmed, but also for the frontal region and the front temporal region the same hair growth, hair restoration, and hair thickening effects as for the crown are confirmed.

Problems solved by technology

In spite of the fact that alopecia causes serious emotional distress due to problems related to appearance, no definite therapy has yet been found.
With regard to androgenetic alopecia in particular, even minoxidil or finasteride cannot give a sufficient therapeutic effect in many cases, and with regard to alopecia areata, there are hardly any effective treatment methods.
Furthermore, since alopecia areata is a recurring disease and also an intractable disease, greatly degrades the appearance, and might cause depression, it is therefore necessary for it to be treated.
With regard to postpartum alopecia, after childbirth, since a large amount of body hair is lost in a short period, coupled with postpartum depression the emotional burden on the patient is large, but there are hardly any therapies.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agent for the treatment of alopecia
  • Agent for the treatment of alopecia
  • Agent for the treatment of alopecia

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0369]Diagnosis and evaluation of test subjects.

[0370]First, prior to administration of a natriuretic peptide preparation, diagnosis and evaluation of test subjects were carried out. Methods for the diagnosis and evaluation of test subjects were as follows.

1. Diagnosis of test subject;

[0371]The test subjects were patients with alopecia areata, androgenetic alopecia, postpartum alopecia, female pattern alopecia, alopecia pityroides, and senile alopecia. Diagnosis and treatment of these test subjects were carried out by the present inventors as physicians.

2. Evaluation of symptoms;

[0372]Clinical classification of alopecia was carried out in accordance with the Classification of the Japanese Dermatological Association, and evaluation of the severity of alopecia areata was carried out in accordance with the above-mentioned ‘USA Alopecia Areata Evaluation Guidelines’, the area of hair loss being classified using 6 grades of S0 to S5 and the hair loss site being classified using 3 grades ...

example 2

1. Production of Gel

[0374]Preparation of a gel containing an NP as an active ingredient was carried out by weighing, as a main agent, 3 mg of any one of human ANP (1-28) (Peptide Institute, Inc.), human BNP-32 (Peptide Institute, Inc.), and human CNP-22 (Peptide Institute, Inc.), dissolving this in 3 mL of purified water to give an NP solution having a concentration of 1000 μg / mL, and mixing 1 mL of this solution with 9 g of Lubrajel NP (ISP Japan Ltd.) by uniform stirring, thus giving an ANP gel, a BNP gel, and a CNP gel having a concentration of 100 μg / g.

[0375]Similarly, 500 μL of the NP solution having a concentration of 1000 μg / mL obtained above was diluted with 500 μL of physiological saline to thus adjust the concentration to 500 μg / mL, and 1 mL of this solution was mixed with 9 g of Lubrajel NP (ISP Japan Ltd.) by uniformly stirring, thus giving an ANP gel, a BNP gel, and a CNP gel having a concentration of 50 μg / g.

2. Production of Ointment (Vaseline Preparation)

[0376]Prepara...

example 3

1. Diagnosis and Treatment of Test Subjects

[0385]Prior to administration of the ANP gel, BNP gel, CNP gel, BNP ointment, and CNP ointment of the present invention, as is routine for dermatological diagnosis and treatment, the test subjects were interviewed regarding age, gender, history of disease, and family history of disease; when an allergic predisposition was suspected, a scratch test against the main allergens and an evaluation thereof were carried out. In dermatological diagnosis and treatment, since there are a relatively large number of patients who have strong immunoreactivity toward a specific allergen, or a disease such as atopic dermatitis that is suspected to be related to having an allergic predisposition, in order to assist diagnosis, an interview with respect to family history and previous history of allergic disease in addition to gender and age, and a scratch test toward the main allergens, are widely carried out as simple supplemental test methods.

[0386]With rega...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Dimensionless propertyaaaaaaaaaa
Login to View More

Abstract

It is an object of the present invention to provide a new agent for the treatment of alopecia, the agent being not only effective and safe for, in particular, alopecia areata, androgenetic alopecia in a male, androgenetic alopecia in a female, female pattern alopecia, postpartum alopecia, seborrheic alopecia, alopecia pityroides, senile alopecia, cancer chemotherapy drug-induced alopecia, and alopecia due to radiation exposure, but also effective for a target having resistance to treatment with minoxidil or finasteride, there being no side effects such as an itching sensation, irritation, or feminization, and no contraindications, the agent suppressing dandruff or having a therapeutic effect for white hair, and the therapeutic effect for alopecia being maintained for a long period even when use of the agent is stopped.The solution means of the present invention is an agent for the treatment of alopecia containing as an active ingredient a C-type natriuretic peptide (CNP), a B-type natriuretic peptide (BNP), a derivative of these NPs, a chimeric peptide of these NPs, or a derivative of a chimeric peptide of these NPs.

Description

TECHNICAL FIELD[0001]The present invention relates to an agent for the treatment and / or prevention of alopecia, dandruff, white hair, and seborrheic scalp, the agent containing as an active ingredient an A-type natriuretic peptide (ANP), a B-type natriuretic peptide (BNP), a C-type natriuretic peptide (CNP), a derivative of these natriuretic peptides (NPs), a chimeric peptide of 2 or more NPs selected from the above NPs, or a derivative of a chimeric peptide of the above NPs (hereinafter, they are collectively called ‘natriuretic peptides (NPs)’).[0002]In particular, the present invention relates to an agent for the treatment and / or prevention of alopecia, dandruff, white hair, and seborrheic scalp, the agent containing as an active ingredient BNP, CNP, a derivative of BNP, a derivative of CNP, a chimeric peptide of CNP or BNP, or a derivative thereof.[0003]The agent for the treatment and / or prevention is expressed simply as an agent for the treatment below.BACKGROUND ART1. Alopecia...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/22A61P17/14C07K14/575
CPCA61K31/14A61K31/506A61K31/573A61K31/7036A61K38/22A61K45/06A61K2300/00A61P17/14A61P37/08A61K8/64A61K9/0014A61Q7/00
Inventor ENDO, KYOKO
Owner ENDO YORI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products